This application Chicagoland TrialNet Clinical Center is in response to the RFA -DK-13-010 Type 1 Diabetes TrialNet Clinical Centers (U01). Here we describe a joint effort from the University of Chicago and Advocate Children's Hospital (ACH) sites (Park Ridge and Oak Lawn, Illinois) and Advocate Health Care (AHC) to create a new Clinical Center in the Chicagoland area. These organizations along with our other affiliate (Lurie Children's Hospital) and partner sites saw over 9000 patients with type 1 diabetes (T1D) in 2012. Together, these practice sites along with other participating key adult and pediatric diabetes practitioners from Chicago reach over 12 million individuals within a two-hour drive of a screening location. The Chicago community, strong supporters of the Juvenile Diabetes Research Foundation (JDRF) and American Diabetes Association (ADA), has been under-represented in clinical trials for Type 1 Diabetes (T1D). This partnership will bring together the resources of major medical centers committed to T1D research and clinical care to reach more of the estimated 100,000 individuals with T1D in the Chicagoland area (about 0.8% of the area population) and their families, as well as the 2000 projected new cases of T1D and their families each year. This outreach will involve diverse communities from some of the wealthiest to some of the most underserved in the United States. We will build on our success in creating the largest database for monogenic diabetes in the United States. We will engage the greater Chicagoland community through innovative social media and direct communications combining media support, direct visits to local practices, community events supported by our institutions and partners and outreach to large networks of faith communities. The University of Chicago has been committed to diabetes research for over 100 years, and together with Advocate Children's Hospital and other partners we will bring a new sense of energy, organization, and purpose to TrialNet recruitment and screening in the Chicagoland region.
Health Impact: Type 1 diabetes is an autoimmune disease affecting over 3 million Americans frequently in childhood and young adulthood, impacting the most productive years of their families and themselves. The cost is disproportionately enormous in terms of direct care, lost earnings and shortened lifespan. This application seeks to increase the number of subjects enrolled in advanced TrialNet clinical trials in the Chicagoland area.
|Ismail, Heba M; Xu, Ping; Libman, Ingrid M et al. (2018) The shape of the glucose concentration curve during an oral glucose tolerance test predicts risk for type 1 diabetes. Diabetologia 61:84-92|
|Culina, Slobodan; Lalanne, Ana Ines; Afonso, Georgia et al. (2018) Islet-reactive CD8+ T cell frequencies in the pancreas, but not in blood, distinguish type 1 diabetic patients from healthy donors. Sci Immunol 3:|
|Vecchio, Federica; Lo Buono, Nicola; Stabilini, Angela et al. (2018) Abnormal neutrophil signature in the blood and pancreas of presymptomatic and symptomatic type 1 diabetes. JCI Insight 3:|
|Redondo, Maria J; Steck, Andrea K; Sosenko, Jay et al. (2018) Transcription Factor 7-Like 2 (TCF7L2) Gene Polymorphism and Progression From Single to Multiple Autoantibody Positivity in Individuals at Risk for Type 1 Diabetes. Diabetes Care 41:2480-2486|
|Sanda, Srinath; Type 1 Diabetes TrialNet Study Group (2018) Increasing ICA512 autoantibody titers predict development of abnormal oral glucose tolerance tests. Pediatr Diabetes 19:271-276|
|Yeo, Lorraine; Woodwyk, Alyssa; Sood, Sanjana et al. (2018) Autoreactive T effector memory differentiation mirrors ? cell function in type 1 diabetes. J Clin Invest 128:3460-3474|
|Redondo, Maria J; Geyer, Susan; Steck, Andrea K et al. (2018) A Type 1 Diabetes Genetic Risk Score Predicts Progression of Islet Autoimmunity and Development of Type 1 Diabetes in Individuals at Risk. Diabetes Care 41:1887-1894|
|Greenbaum, Carla J; Speake, Cate; Krischer, Jeffrey et al. (2018) Strength in Numbers: Opportunities for Enhancing the Development of Effective Treatments for Type 1 Diabetes-The TrialNet Experience. Diabetes 67:1216-1225|
|Redondo, Maria J; Geyer, Susan; Steck, Andrea K et al. (2018) TCF7L2 Genetic Variants Contribute to Phenotypic Heterogeneity of Type 1 Diabetes. Diabetes Care 41:311-317|
|Sosenko, Jay M; Geyer, Susan; Skyler, Jay S et al. (2018) The influence of body mass index and age on C-peptide at the diagnosis of type 1 diabetes in children who participated in the diabetes prevention trial-type 1. Pediatr Diabetes 19:403-409|
Showing the most recent 10 out of 52 publications